, reserving infusion slots, identifying alternative infusion sites) may be needed to increase access to IV remdesivir
Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study Andrew Ip, Jaeil Ahn, Yizhao Zhou, Andre
HCQ and HCQ/AZ are not effective therapies for outpatient treatment of SARV-CoV-2 infection
This topic will address the management of adult patients with acute COVID-19 in the outpatient setting, including self-care advice, telehealth and outpatient
This article summarizes the prevention, diagnosis, and treatment of COVID-19, with a
Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) Funder: The National Heart, Lung, and
During the four-year period December 2019–December 2023, the COVID-19 pandemic caused more than 770 million cases and 7 million deaths worldwide, with an
Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial
Several randomized placebo-controlled clinical trials are underway to evaluate hydroxychloroquine’s safety and efficacy in the prevention and treatment of COVID-19 in both inpatient and outpatient populations [ 6 ]
One approach to reducing the impact of COVID-19 on the healthcare system is
Data informing outpatient management strategies continue to evolve, and the approach described here is based upon a rapidly
Hydroxychloroquine or chloroquine alone or in combination with azithromycin is not recommended outside of a clinical trial by the NIH, the Infectious Diseases Society of America, or the American College of Physicians for treatment of COVID-19
Some researchers have promoted chloroquine and hydroxychloroquine for the treatment and prevention of ClinicalTrials
A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)
6 No significant difference was observed between the HCQ treatment group (one-time 800-mg dose followed by 600 mg/day for 5 days) and placebo COVID-19 prevention and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology
INTRODUCTION
Ivermectin for Early Covid-19 Multiple medications in common use have been considered for the treatment of Covid-19
The COVID-19 Early Treatment Study was funded by the Bill & Melinda Gates Foundation (INV-017062) through the COVID-19 Therapeutics Accelerator